These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23220074)

  • 1. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
    Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
    Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
    Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
    Della Corte C; Carpino G; De Vito R; De Stefanis C; Alisi A; Cianfarani S; Overi D; Mosca A; Stronati L; Cucchiara S; Raponi M; Gaudio E; Byrne CD; Nobili V
    PLoS One; 2016; 11(12):e0168216. PubMed ID: 27977757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
    Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
    Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation.
    Fedor DM; Adkins Y; Mackey BE; Kelley DS
    Metab Syndr Relat Disord; 2012 Jun; 10(3):175-80. PubMed ID: 22242926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
    Zöhrer E; Alisi A; Jahnel J; Mosca A; Della Corte C; Crudele A; Fauler G; Nobili V
    Appl Physiol Nutr Metab; 2017 Sep; 42(9):948-954. PubMed ID: 28511023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease.
    Nobili V; Bedogni G; Donati B; Alisi A; Valenti L
    J Med Food; 2013 Oct; 16(10):957-60. PubMed ID: 24074360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
    Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
    BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.
    Alisi A; Bedogni G; Baviera G; Giorgio V; Porro E; Paris C; Giammaria P; Reali L; Anania F; Nobili V
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1276-85. PubMed ID: 24738701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
    Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of liver steatosis through fish oil supplementation: correlation of oxidative stress with insulin resistance and liver fatty acid content.
    Espinosa A; Valenzuela R; González-Mañán D; D'Espessailles A; Guillermo Gormaz J; Barrera C; Tapia G
    Arch Latinoam Nutr; 2013 Mar; 63(1):29-36. PubMed ID: 24167955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy.
    Colicchio P; Tarantino G; del Genio F; Sorrentino P; Saldalamacchia G; Finelli C; Conca P; Contaldo F; Pasanisi F
    Ann Nutr Metab; 2005; 49(5):289-95. PubMed ID: 16088092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.
    Boyraz M; Pirgon Ö; Dündar B; Çekmez F; Hatipoğlu N
    J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):121-7. PubMed ID: 26316434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.